Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
) at the University of Oslo, there are three co-PIs; Florent Sebbane at, INSERM, Lille, France , Philip Slavin, University of Stirling, Stirling, UK and Ulf Büntgen, University of Cambridge, Downing Place, Cambridge
-
) at the University of Oslo, there are three co-PIs; Florent Sebbane at, INSERM, Lille, France , Philip Slavin, University of Stirling, Stirling, UK and Ulf Büntgen, University of Cambridge, Downing Place, Cambridge
-
) at the University of Oslo, there are three co-PIs; Florent Sebbane at, INSERM, Lille, France , Philip Slavin, University of Stirling, Stirling, UK and Ulf Büntgen, University of Cambridge, Downing Place, Cambridge
-
, University of Cambridge, Downing Place, Cambridge, UK . The overall aim of the project is to reconstruct the environmental, biological and societal drivers behind plague outbreaks in Eurasia between 1300 and
-
. https://www.prima.uio.no/english/ . We are now recruiting a postdoc to join a team-based alliance and contribute to the next generation immunotherapy strategies. Advances in genetic engineering combined
-
studies, including the Norwegian population cohorts (e.g., MoBa), the UK Biobank, and the ABCD and ADNI studies. For more information https://www.med.uio.no/klinmed/english/research/groups/precision
-
, University of Cambridge, Downing Place, Cambridge, UK . The overall aim of the project is to reconstruct the environmental, biological and societal drivers behind plague outbreaks in Eurasia between 1300 and
-
of Stirling, Stirling, UK and Ulf Büntgen, University of Cambridge, Downing Place, Cambridge, UK . The overall aim of the project is to reconstruct the environmental, biological and societal drivers behind
-
the project is to reconstruct the environmental, biological and societal drivers behind plague outbreaks in Eurasia between 1300 and 1900 AD. A short description of the project can be found here: https
-
Council of Norway. https://www.prima.uio.no/english/. We are now recruiting a postdoc to join a team-based alliance and contribute to the next generation immunotherapy strategies. The current position is a